Inflexion-backed Rosemont to acquire Lucis Pharma.

Inflexion-backed Rosemont, a pharmaceutical company, agreed to acquire Lucis Pharma, a specialist pharmaceutical business in the UK. Financial terms were not disclosed. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets. We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practice for their care," Howard Taylor, Rosemont CEO.